Fenbendazole for humans cancer is an antiparasitic medicine used to treat gastrointestinal parasites such as pinworms, giardia, roundworms, hookworms, and Taenia solium. It is also widely prescribed for dogs with intestinal parasites, but it has been reported to treat human cancer as well. It is unclear why human cancers have been successfully treated with this drug, and further research is needed. However, this drug has not been approved by the FDA and should only be administered under a doctor’s supervision.
The anthelmintic medicine is thought to work by inhibiting microtubules, a protein scaffolding that gives shape and structure to cells. Textbook depictions of cells often show various organelles floating in amorphous bags of liquid, but they establish their shape through the cytoskeleton. These structures are primarily composed of a protein called tubulin. When fenbendazole for humans cancer is administered, it interferes with the polymerization of tubulin and causes cells to lose their structural integrity, leading to apoptosis.
Scientists have also found that this medication may prevent cancer cell mutations by increasing p53 levels in the cells. P53 is a crucial tumor suppressor gene, and when its expression is increased in the cells, it prevents the cellular mutations that lead to cancer formation. Scientists have also discovered that a natural compound, curcumin, can increase healthy p53 levels in the body and prevent cancer cells from forming.
Another possible reason that fenbendazole for humans Cancer works against cancer cells is because it does not develop resistance in the body. This is important because most chemotherapeutic drugs become ineffective over time as the cancer becomes resistant to their effects. This is because the cancer cells build a molecular shield around themselves, preventing chemotherapy drugs from being able to penetrate and destroy them. Fenbendazole, on the other hand, does not develop resistance in the cells and can therefore be taken continuously as a long-term treatment for cancer.
A recent study published in Scientific Reports showed that fenbendazole can induce apoptosis and inhibit cell growth in colorectal cancer cells. The research team used a cell model with different concentrations of fenbendazole for humans and observed the results over time. They found that the higher the dose of fenbendazole, the more effective it was at inducing apoptosis. In addition, fenbendazole caused the phosphorylation of SLC7A11 in the cancer cells, which is required for the formation of ferroptosis.
The researchers also found that fenbendazole could suppress the proliferation of colorectal cancer cells by inducing apoptosis, inhibiting cell growth, and regulating multiple cellular pathways. The apoptosis was mediated by multiple mechanisms, including the destabilization of microtubules and inhibition of tubulin polymerization. Additionally, fenbendazole significantly increased the degradation of the cyclin B1 protein and the ubiquitination of its substrates. It was found that fenbendazole also blocks glucose absorption in cancer cells, which is known as the Warburg effect (reference). Inhibition of this process slows down tumor progression and increases the sensitivity of the cells to cytotoxic drugs. This is the first time that a natural substance has been shown to induce apoptosis and block cancer cell growth.
